Santofimia-Castaño, Patricia
Huang, Can
Liu, Xi
Xia, Yi
Audebert, Stephane http://orcid.org/0000-0002-9409-2588
Camoin, Luc http://orcid.org/0000-0002-1230-4787
Peng, Ling http://orcid.org/0000-0003-3990-5248
Lomberk, Gwen http://orcid.org/0000-0001-5463-789X
Urrutia, Raul http://orcid.org/0000-0002-1640-6780
Soubeyran, Philippe http://orcid.org/0000-0002-5876-3217
Neira, Jose Luis
Iovanna, Juan http://orcid.org/0000-0003-1822-2237
Article History
Received: 19 November 2021
Accepted: 12 July 2022
First Online: 22 July 2022
Competing interests
: J.I. is co-founder of PanCa Therapeutics and PedictingMed. P.S.C., Y.X., L.P., J.L.N., and J.I. are inventors of the Patent “NUPR1 INHIBITION FOR TREATING CANCER”, Application number WO-2019229236-A1. The other authors declare no competing interests. This work was supported by La Ligue Contre le Cancer, INCa, Canceropole PACA, and INSERM. C.H. and X.L. are recipient of the predoctoral fellowship from China Scholarship Council (CSC).